Capital Insights
From Mediocre Portfolios to 18% Returns: EFM’s Radical Transparency in Private Markets
Tired of mediocre returns? Emerging Funds Management (EFM) Founding Partner Surendra Pather explains how his firm fills the bank funding gap for developers while delivering 18% returns to sophisticated investors through a radical, transparent fiduciary model.
Silent Pain and Smart Monitors: The High-Stakes Race to De-Risk the Operating Theatre
Anesthesia has long been considered more “art” than science, leaving clinicians to manage high-stakes sedation with aging tools. Cortical Dynamics is changing the clinical reality with BARM 2.0—an AI-powered monitor that provides real-time visibility into the brain’s response to pain and sedation, backed by a global licence and cooperation agreement with Philips and a decade of R&D.
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
In the high-stakes theater of the cath lab, cardiogenic shock is the ultimate emergency. Now, a PhD in fluid mechanics and a frontline cardiologist are deploying a “collapsible” breakthrough to disrupt a 30-year monopoly. The Engineer’s Mission For Dr. Martin Cook, the stakes of medical engineering aren’t measured in blueprints, but in heartbeats. A PhD […]
The Blue-Collar ‘Muscle’ Behind Australia’s $100bn Pipeline: One Key Resources Eyes Expansion
As Australia faces a “perfect storm” of low unemployment and an ambitious $100bn project pipeline, One Key Resources MD Ben Lewis explains why the next five years will be defined by the “muscle power” required to deliver the nation’s energy and infrastructure goals.
Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis
Cartherics is bridging the gap in women’s health by utilising iPSC-derived Natural Killer cells to target both ovarian cancer and endometriosis. With a proprietary manufacturing facility and a lead candidate heading to Phase 1 trials, the company is industrialising cell therapy to solve a multi-billion dollar unmet need.
The Billion-Dollar Blind Spot: The Australian Tech Making ‘Invisible’ Decay a Visible Asset for Investors
Incisive Technologies is moving dentistry from “restorative” to “preventative.” By detecting decay at 30 microns—long before it appears on an X-ray—their FDA-approved BlueCheck tool is eliminating the industry’s “watch and wait” mantra and opening a massive new frontier for clinical and at-home oral health monitoring.
How to Target Wholesale Investors in Australia
Targeting wholesale investors effectively means going beyond the legal definition of who qualifies and understanding who is actually likely to invest in your specific opportunity. Australia has a substantial and growing wholesale investor community, but it is not homogeneous. The investors who back seed-stage biotech companies are not the same investors who deploy into private […]
Wholesale Investor Email List: Why Quality Beats Quantity
When founders search for a wholesale investor email list, what they actually need is access to investors who are actively looking to deploy capital into private market opportunities. The distinction matters because a raw list of email addresses and a curated network of engaged wholesale investors produce fundamentally different results. This article explains why opt-in […]
Wholesale Investor Marketing Regulations in Australia
Marketing investment opportunities to wholesale investors in Australia is subject to a distinct regulatory framework that differs significantly from retail financial product marketing. While the Section 708 exemptions remove the requirement for a prospectus, they do not eliminate all regulatory obligations. Companies that misunderstand these boundaries risk ASIC enforcement, investor claims, and reputational damage. This […]
Backed By Leading Investment Groups and Family Offices
